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Background GP2015 is a proposed etanercept biosimilar. Objectives To demonstrate equivalent efficacy, and comparable safety and immunogenicity of GP2015 and the etanercept originator (ETN, Enbrel â ) in patients with moderate-to-severe chronic plaque-type psoriasis. Methods In total, 531 eligible patients were randomized 1 : 1 to self-administer GP2015 or ETN twice weekly subcutaneously. Patients with ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were rerandomized to continue the same treatment on a once-weekly dosing schedule or to undergo a sequence of three treatment switches between GP2015 and ETN until week 30. Thereafter, patients continued treatment with the product they had been assigned to last, up to week 52. Results The difference in PASI 75 (75% improvement from baseline PASI score) response rates at week 12 between GP2015 and ETN (primary end point) was À2Á3%. The 95% confidence interval (À9Á85 to 5Á30) was well contained within the prespecified margin range of À18 to 18. The incidence of treatment-emergent adverse events up to week 52 was comparable between continued GP2015 (59Á8%) and ETN (57Á3%); switching treatments revealed comparable safety profiles. Antidrug antibodies, all non-neutralizing, were limited to five patients on ETN during treatment period 1, and one patient in the switched ETN group, who had been treated with GP2015 for 12 weeks at the time of the finding.
Conclusions The EGALITY study demonstrated equivalent efficacy and comparable safety and immunogenicity of GP2015 and ETN. The study results provide the final clinical confirmation of biosimilarity and contribute to the totality of the evidence proposing that GP2015 is an etanercept biosimilar.
What's already known about this topic?
• Etanercept is a tumour necrosis factor inhibitor successfully used in clinical practice for the treatment of various immune-mediated inflammatory diseases.
• A biosimilar is a biological medicinal product designed to be essentially the same as the reference biologic (authorized biological medicine -the originator).
• Biosimilarity is established on the basis of the totality of the evidence based on the data from analytical, nonclinical, pharmacokinetic and clinical comparisons with the originator product.
What does this study add?
• GP2015 is a proposed etanercept biosimilar.
• EGALITY, the first etanercept biosimilar study in patients with moderate-to-severe chronic plaque-type psoriasis, was conducted with the purpose of gathering confirmatory clinical evidence of biosimilarity between GP2015 and the etanercept originator in a sensitive indication.
• GP2015 was shown to possess equivalent efficacy to and comparable safety and immunogenicity with the etanercept originator, with no new or unexpected safety issues.
Etanercept is a recombinant human tumour necrosis factor (TNF)-a receptor-p75Fc fusion protein that binds TNF-a with high affinity and specificity, rendering it biologically inactive. [1] [2] [3] [4] TNF-a is a naturally occurring cytokine implicated in a range of immune-mediated inflammatory diseases (IMIDs). Etanercept has been used successfully in clinical practice for more than 15 years and is approved for the treatment of multiple IMIDs, including plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis. Biological products such as etanercept are derived from unique bioengineered cells or organisms. 5, 6 Biosimilars are follow-on versions of authorized biological products. 7 Regulatory authority guidelines require evaluation and confirmation of biosimilarity between the active substance of a proposed biosimilar and the approved originator based on the totality of evidence derived from a complete data package, comprising physicochemical, biological, nonclinical and clinical data. 8, 9 GP2015 is a proposed etanercept biosimilar. The bioequivalence of GP2015 with the etanercept originator product (ETN) has been demonstrated in nonclinical 10 and pharmacokinetic studies. 11 The EGALITY study in psoriasis with GP2015 was conducted to contribute key confirmatory clinical data as part of the totality of biosimilarity evidence. The objective of this study was to demonstrate equivalence in efficacy and to compare the safety and immunogenicity of GP2015 and ETN in patients with moderate-to-severe chronic plaque-type psoriasis. The effects of repeated treatment switching between GP2015 and ETN on efficacy, overall safety and immunogenicity were also evaluated.
Patients and methods
EGALITY was a multicentre, randomized, double-blind, confirmatory efficacy and safety study conducted from 24 June 2013 to 30 March 2015, across 74 centres in 11 European countries and South Africa (NCT01891864).
Study population
Eligible patients included men or women ≥ 18 years of age, with active but clinically stable chronic plaque-type psoriasis diagnosed ≥ 6 months before baseline, who had previously received phototherapy or systemic psoriasis therapy at least once or who were candidates for such therapies in the opinion of the investigator. Moderate-to-severe psoriasis at baseline was defined as a Psoriasis Area and Severity Index (PASI) score ≥ 10, an Investigator's Global Assessment modified 2011 (IGA mod 2011) score ≥ 3 (based on a scale of 0-4) and ≥ 10% body surface area affected by plaque-type psoriasis. Key exclusion criteria were any previous exposure to etanercept; exposure to TNF antagonists or other biological immunomodulating agents in the 6 months prior to randomization; ongoing use of prohibited psoriasis treatments such as topical corticosteroids or ultraviolet therapy, or prohibited nonpsoriasis treatments (all other prior nonpsoriasis concomitant treatments had to be on a stable dose for ≥ 4 weeks before baseline); presence of active systemic infections in the 2 weeks prior to baseline; or latent tuberculosis detected by imaging or positive QuantiFERON â TB Gold test. Detailed exclusion criteria are listed in Appendix S1 (see Supporting Information).
Study design
The study consisted of four periods ( Fig. 1) : screening, treatment period 1 (weeks 0-12), treatment period 2 (weeks [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and an extension phase (weeks 31-52). In treatment period 1, patients were randomized 1 : 1 to self-administer 50 mg GP2015 or 50 mg ETN (Enbrel â ; Amgen Inc., Thousand Oaks, CA, U.S.A.; European Union authorized) twice weekly, subcutaneously. In treatment period 2, patients who had achieved ≥ 50% improvement in PASI (PASI 50) from baseline at week 12 were rerandomized either to continue the same treatment on a once-weekly dosing schedule (named 'continued GP2015' and 'continued ETN' groups, respectively) or to undergo a sequence of three treatment switches between GP2015 and ETN at 6-weekly intervals until week 30 (named 'switched GP2015' and 'switched ETN' groups, respectively). During the extension phase, patients continued to receive the same treatment received during the final 6 weeks of treatment period 2 (randomization and other study details in Appendix S1; see Supporting Information). This study was conducted in accordance with the ethical principles derived from the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practices and in compliance with local regulatory requirements, and was reviewed and approved by the independent ethics committee or institutional review board for each centre. All patients provided written informed consent before entering the study.
Efficacy assessments
The primary end point was the PASI 75 response rate (proportion of patients showing ≥ 75% improvement in PASI score from baseline visit) after the first 12 weeks of treatment. The main secondary end point was the percentage change from baseline in PASI score up to week 12. Other efficacy variables assessed at all time points up to week 52 included: (i) PASI 50, 75 and 90 response rates; (ii) observed PASI score; (iii) percentage change from baseline in PASI score; and (iv) IGA mod 2011 score assessed using a five-point rating scale 12 (Table S1; see Supporting Information).
Pharmacokinetic assessments
Trough serum concentrations of etanercept were assessed at baseline and at weeks 2, 4, 8 and 12 in a subset of 147 patients. The etanercept serum concentrations were quantified using a validated enzyme-linked immunosorbent assay (detailed assay methodology in Appendix S1; see Supporting Information).
Safety assessments
Adverse event monitoring and injection-site reactions (ISRs) were assessed at all visits. Adverse events of special interest were defined by preferred terms encompassing all of the special warnings and precautions given on the label for ETN. 6 
Immunogenicity assessments
The antidrug antibody (ADA) assessment and analysis followed a tiered approach, and included a screening assay followed by a confirmatory specificity assay and a competitive ligand binding assay to assess the neutralizing capacity of ADAs (Appendix S1; see Supporting Information).
Statistical analysis
A sample size of approximately 546 patients to maintain 464 evaluable patients with an assumed dropout and major protocol deviation rate of 15% was planned to provide a power of 90% to show therapeutic equivalence between GP2015 and ETN.
Based on the statistical hypothesis, therapeutic equivalence in terms of PASI 75 was to be established if the 95% confidence interval (CI) for the difference in the PASI 75 response rates was contained within the prespecified margin range (À18 to 18%). Based on an observed effect size of 45-46% in former placebo-controlled ETN (Enbrel) studies, 3, 13 an equivalence margin of 18% was chosen, so that ≥ 60% of the treatment effect had to be maintained. Primary analysis was performed using a logistic regression model that included treatment groups (GP2015 or ETN), body weight categories and prior systemic therapy as stratification factors in the model. The stratification-factor-adjusted treatment differences between GP2015 and ETN, as well as the corresponding 95% CIs, were derived from the regression model. The primary efficacy analysis was based on the per protocol set (PPS), which consisted of all patients who completed the study until week 12 without major protocol deviations. Dropouts due to unsatisfactory therapeutic effect were included in the PPS as nonresponders provided they received at least 4 weeks of treatment. The analysis was repeated on the full analysis set (FAS) following the intent-totreat principle as a sensitivity analysis.
The main secondary efficacy variable was analysed using a powered mixed-model repeated-measures approach 14 and an averaged treatment effect approach using an ANCOVA model. No imputation for missing PASI scores or components of PASI scores was performed. Both approaches had a prespecified margin range (À15 to 15%) to claim therapeutic equivalence and were performed on the PPS and repeated on the FAS. A Patient disposition from baseline to week 52 (full analysis set). Of the 14 patients who did not enter treatment period 2, five did not achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 (three others who also did not achieve PASI 50 continued erroneously in treatment period 2); seven patients discontinued immediately after week 12 (three patients were not rerandomized, four patients were rerandomized but did not take any study drug in treatment period 2) and two patients achieved PASI 50 at week 12 but had no data beyond week 12. Of the five patients who did not enter the extension phase, two patients discontinued at their own decision, one discontinued due to a treatment-emergent adverse event, one discontinued due to lack of efficacy and one was lost to follow-up. The switched GP2015 treatment group includes patients who switched to treatment sequence ETN?GP2015?ETN at 6-week intervals during treatment period 2, and the switched ETN treatment group includes patients who switched to treatment sequence GP2015?ETN?GP2015 at 6-week intervals during treatment period 2. During the extension phase, patients continued receiving the last treatment received during treatment period 2. ETN, etanercept originator product.
smaller equivalence margin than for the primary analysis was chosen because of a lower effect size for the more sensitive variable percentage change from baseline in PASI score. Additional details on efficacy analyses and definitions of datasets are provided in Appendix S1 (see Supporting Information).
Results
Among the 531 randomized patients, the dropout rate was low (GP2015: n = 8, 3%; ETN: n = 12, 4Á5%) during the initial 12 weeks of treatment. The patient disposition is shown in Figure 2 . The baseline demographics and disease characteristics of the patients were similar across the two treatment groups (Table 1) .
Efficacy

Primary end point
The treatment difference between GP2015 and ETN (GP2015 À ETN) for adjusted PASI 75 response rates in the PPS (n = 480) at week 12 was À2Á3 (73Á4% vs. 75Á7%; 95% CI À9Á85 to 5Á30) (Fig. 3) . As the 95% CI was contained within the prespecified interval (-18 to 18%), this result demonstrated therapeutic equivalence between GP2015 and ETN. The primary end point analysis was further supported by the analysis on the FAS (Fig. 3) .
Main secondary end point
The mean percentage change from baseline to week 12 in PASI score was similar between GP2015 and ETN (Fig. 4a) . The 95% CIs for the least-squares mean differences in percentage change from baseline in PASI score (GP2015 À ETN) up to week 12 for both the mixed-model repeatedmeasures (À0Á64, 95% CI À3Á47 to 2Á20) and the averaged treatment effect (À0Á88, 95% CI À3Á61 to 1Á85) approaches were contained within the prespecified interval of À15 to 15% (Fig. 4b) . These findings on the PPS were supported by similar analyses on the FAS ( Fig. S1 ; see Supporting Information).
Other end points
From baseline to week 52, the mean scores and percentage changes from baseline in PASI score at all time points were comparable between the continued GP2015 and ETN groups in the PPS, and between the pooled continued and pooled switched treatment groups (Figs S2, S3; see Supporting Information). In all treatment groups, the adjusted PASI 75 and PASI 90 response rates gradually increased over time until week 30 and thereafter remained stable until week 52 ( Fig. 5 ; Fig. S4 ; see Supporting Information). The adjusted PASI 50 response rate increased until week 12, at which time PASI 50 nonresponders were discontinued from the study (Fig. 5) . The PASI 50 response rate remained stable from week 18 until week 52 in all treatment groups ( Fig. 5; Fig. S4 ). At baseline, the majority of patients in the GP2015 (72Á0%, 172 of 239) and ETN (68Á9%, 166 of 241) groups had an IGA mod 2011 score of 3. At week 12, the proportion of IGA mod 2011 responders (score of '0' or '1') was numerically higher in the GP2015 group than in the ETN group (Fig. 6) .
Pharmacokinetic results
Trough concentrations indicated that drug concentrations reached steady-state systemic levels from week 2 onwards in both treatment arms, consistent with the reported half-life of 3-4 days for etanercept, 6 and were maintained throughout the 12-week period of evaluation in both treatment groups (Fig. 4c) . Mean etanercept trough levels at weeks 2, 4, 8 and 12, as well as the variability of etanercept trough levels, were similar within and across both treatment groups, indicating In the etanercept originator product group, one (0Á4%) patient belonged to the 'unknown' category and another one (0Á4%) to the 'other' category. sustained exposure to etanercept and comparable clearance of GP2015 and ETN.
Safety results
The median duration of exposure until 12 weeks was similar between the GP2015 and ETN groups (81 days), and until 52 weeks was similar between the continued GP2015 and ETN groups (358 days).
The number of patients with at least one treatment-emergent adverse event (TEAE) up to week 52 was similar between the continued GP2015 (n = 98, 59Á8%) and the continued ETN groups (n = 98, 57Á3%); and between the switched GP2015 (n = 61, 61%) and switched ETN groups (n = 57, 59%) ( Table 2 ). The incidences of serious adverse events, study discontinuation due to TEAEs, and treatment-related TEAEs were similar between the two continued treatment groups and between the two switched treatment groups ( Table 2; Table S2 ; see Supporting Information).
The incidence of adverse events of special interest was higher for continued GP2015 vs. continued ETN (11Á0% vs. 4Á7%) and for switched GP2015 (11, 11Á0%) vs. switched ETN (five, 5%) (Table S3 ; see Supporting Information). Malignant melanoma in situ was reported in one patient in the continued GP2015 group. One patient died during the study, due to cardiopulmonary failure (in the ETN group in treatment period 1). The death was suspected to be due to concomitant conditions such as type 2 diabetes mellitus and was not suspected to be treatment related.
ISRs were reported in 13 (4Á9%) patients in the GP2015 group and in 38 (14Á2%) patients in the ETN group until week 12. Most ISRs were mild in both treatment groups (11 patients, 4Á2% and 32 patients, 12Á0%, respectively). In the continued GP2015 and continued ETN groups, ISRs were reported in 14 (8Á5%) and 27 (15Á8%) patients, respectively, until week 52; most were mild (13, 7Á9% vs. 23, 13Á5%, respectively).
Immunogenicity
Five patients (1Á9%) in the ETN group (n = 267) had a confirmed positive low-titre non-neutralizing ADA result during treatment period 1. These responses were detected within the first 4 weeks of treatment, and the respective patients had ADA-negative results at all subsequent visits. One patient (1%) in the switched ETN group (n = 90) showed a confirmed positive low-titre non-neutralizing ADA result at week 36 (the patient was receiving GP2015 for 12 weeks at the time of the finding), with no other confirmed ADA results in previous or subsequent visits. No further patients in the study had confirmed positive ADA samples.
Discussion
The results of this study confirm the biosimilarity that was established with all previous analytical comparisons with the reference product, in that equivalent efficacy was demonstrated, as well as similar safety and immunogenicity of GP2015 to ETN in a highly sensitive, generally immunocompetent population. In patients with moderate-to-severe chronic plaque-type psoriasis, GP2015 was shown to be equivalent to ETN regarding the PASI 75 response rate after 12 weeks of treatment. This primary end point result was corroborated by the main secondary efficacy outcome. Other efficacy outcomes up to week 52 established both the equivalence of efficacy and lack of difference between long-term treatment with GP2015 and ETN. Switching these two treatments did not have any negative effect on efficacy. A PASI 75 response rate was chosen to demonstrate equivalence between GP2015 and ETN as it is established as a clinically meaningful end point in clinical trials, and is considered by clinicians to be indicative of success with treatment in patients with psoriasis. 15 The PASI 75 response rates observed at week 12 in this study were highly comparable between the treatment groups (GP2015, 73Á4%; ETN, 75Á7%) even though they were above the upper range of those reported at week 12 in previous studies with ETN in this indication (47-62%). 3, 13, [16] [17] [18] Several possible factors could have contributed to this difference. The biosimilar study design involves use of two active treatment arms lacking a placebo comparator, and it has been previously reported that using only active treatment arms shows an increased effect size compared with placebo-controlled studies.
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The PASI 75 analysis was based on the PPS, excluding protocol violators and dropouts, as it is considered the more sensitive population in equivalence or noninferiority trials, 23, 24 unlike the FAS, which is based on the intent-to-treat principle and the last-observation-carried-forward approach, used in pivotal trials. Also, patients in the EGALITY study had a lower body weight/body mass index compared with published data 25 (which may have an impact given the fixed-dose regimen) and a higher baseline PASI score and higher affected body surface area than patients in the ETN pivotal studies. 3, 13 Of particular note, the long-term response rates (at 24-30 weeks) observed in this study (Fig. 5) were similar to those observed in previous ETN studies. 17, 18 Other biosimilar studies have also reported higher response rates for the primary efficacy parameter compared with the pivotal studies for the originator product. 21, [26] [27] [28] Moreover, the EGALITY study was designed to establish similarity between GP2015 and ETN 
Patients experiencing multiple events were counted only once within each treatment group. PTs with events occurring with an incidence ≥ 2% in any of the treatment groups in the OA safety set are presented and sorted by descending order of frequency within the continued GP2015 column. AE terms are coded using MedDRA version 17.0. Switched GP2015: Switched to treatment sequence ETN>GP2015>ETN in period 2 and continued with ETN in extension period. Switched ETN: Switched to treatment sequence GP2015>ETN>GP2015 in period 2 and continued with GP2015 in extension period. AE, adverse event; ETN, etanercept originator product; MedDRA, medical dictionary for regulatory activities; OA, overall analysis; PT, preferred term; SAE, serious adverse event; SOC, system organ class; TEAE, treatment-emergent adverse event.
in terms of PASI 75 response, and was not aimed at assessing changes in PASI 75 response with treatment over time. The EGALITY trial, establishing the biosimilarity of GP2015 and ETN, contained specific study design attributes, as recommended by health authorities 9 and further discussed in the literature. 29, 30 These include use of an equivalence design with prespecified comparability margins justified on both statistical and clinical grounds by using the data of the originator product, selection of an indication considered most sensitive for the comparison, and inclusion of applicable stratification factors in the statistical model. 9, 29, 30 Patients with psoriasis constitute a suitable population to demonstrate biosimilarity for TNF-a inhibitors, because of the enhanced sensitivity for detecting potential differences in clinical efficacy and immunogenicity in this indication compared with other approved disease conditions. 30 Also, in psoriasis, the selected dosing regimen of 50 mg twice weekly falls into the linear phase of the dose-response curve, in which differences in dose can translate into differences in efficacy. 3 In addition, there is generally no concomitant immunosuppressive therapy in psoriasis treatment with etanercept, resulting in an unbiased and sensitive detection of any potential difference in immunogenicity.
In a preceding pharmacokinetic study in healthy volunteers, the pharmacokinetics of GP2015 were shown to be bioequivalent to those of ETN. 11 In this study, trough serum concentration levels of GP2015 or ETN measured after multiple subcutaneous doses were similar within and across both treatment groups, providing further evidence of similar pharmacokinetics of GP2015 and ETN. The incidence of TEAEs up to week 52 was generally comparable between the treatment groups, and no new or unexpected safety issues were reported. Overall, the safety profiles of both GP2015 and ETN were in line with previous large-scale ETN studies. 3, 13 The incidence of ISRs up to 12 weeks was lower with GP2015 (4Á9%) than with ETN (14Á2%), while the incidence in the ETN group was consistent with those reported in previous ETN studies (13% 3 and 18% 13 ). Although the reasons for the lower incidence of ISRs cannot be fully elucidated, a possible reason could be the difference in formulation between the two products, as has been reported in other biosimilar studies. 21 The higher incidence of TEAEs of special interest reported with GP2015 during the study was not caused by an increased number of events in any specific system organ class, but was due to events spread across several system organ classes, with most occurring in just one patient each in the continued GP2015 group vs. none in the continued ETN group. Safety was not affected by switching treatments. Etanercept is known to have a lower incidence of immunogenicity than other TNF-a inhibitors. 31, 32 The incidence of ADAs during the study was low and consistent with that reported in other large-scale ETN trials in psoriasis; 3,13,16 six patients were ADA positive and all lacked neutralizing antibodies. Switching from ETN to GP2015 or vice versa did not lead to increased ADA formation.
In conclusion, the efficacy of GP2015 was equivalent to that of ETN in patients with moderate-to-severe chronic plaque-type psoriasis. There were no clinically meaningful differences in efficacy, safety or immunogenicity between GP2015 and ETN up to 52 weeks of treatment. No new or unexpected safety issues were reported, and the safety profiles of GP2015 and ETN were similar to those observed in previous ETN studies. Switching treatments did not impact efficacy, safety or immunogenicity. The study results provide clinical confirmation of biosimilarity and contribute to the totality of the evidence proposing GP2015 as an etanercept biosimilar.
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